Literature DB >> 23727028

Circulating cell free DNA: Preanalytical considerations.

Safia El Messaoudi1, Fanny Rolet, Florent Mouliere, Alain R Thierry.   

Abstract

Despite the growing interest in circulating cell-free DNA (ccfDNA) analysis in various clinical fields, especially oncology and prenatal diagnosis, few studies on sample handling have been reported and no analytical consensus is available. The lack of consistency between the various protocols for sample handling and the techniques used for ccfDNA analysis is one of the major obstacles in translating ccfDNA analysis to clinical practice. Although this point is highlighted regularly in the published reviews on ccfDNA analysis, no standard operating procedure currently exists despite several ongoing clinical studies on ccfDNA analysis. This review examines the preanalytical parameters potentially affecting ccfDNA concentration and fragmentation at each preanalytical step from blood drawing to the storage of ccfDNA extracts. Analysis of data in the literature and our own observations revealed the influence of preanalytical factors on ccfDNA analysis. Based on these data, we determined the optimal preanalytical protocols for ccfDNA analysis and ultimately, a guideline for the translation of ccfDNA analysis in routine clinical practice.
Copyright © 2013 Elsevier B.V. All rights reserved.

Keywords:  BRAF; Circulating cell-free DNA; DII; DNA integrity index; Diagnosis; EDTA; KRAS; Preanalytical handling; Q-PCR; RT; Stability; Standard operating procedure; ccfDNA; circulating cell-free DNA; ethylenediaminetetraacetic acid; quantitative polymerase chain reaction; room temperature; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog [GenBank: NG_007524.1]; v-raf murine sarcoma viral oncogene homolog B1 [GenBank: NG_007873.2]

Mesh:

Substances:

Year:  2013        PMID: 23727028     DOI: 10.1016/j.cca.2013.05.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  155 in total

Review 1.  Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.

Authors:  Francesca Riva; Oleksii I Dronov; Dmytro I Khomenko; Florence Huguet; Christophe Louvet; Pascale Mariani; Marc-Henri Stern; Olivier Lantz; Charlotte Proudhon; Jean-Yves Pierga; Francois-Clement Bidard
Journal:  Mol Oncol       Date:  2016-01-22       Impact factor: 6.603

2.  Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.

Authors:  Alain R Thierry; Brice Pastor; Zhi-Qin Jiang; Anastasia D Katsiampoura; Christine Parseghian; Jonathan M Loree; Michael J Overman; Cynthia Sanchez; Safia El Messaoudi; Marc Ychou; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2017-04-11       Impact factor: 12.531

3.  Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

Authors:  Alain R Thierry; Florent Mouliere; Safia El Messaoudi; Caroline Mollevi; Evelyne Lopez-Crapez; Fanny Rolet; Brigitte Gillet; Celine Gongora; Pierre Dechelotte; Bruno Robert; Maguy Del Rio; Pierre-Jean Lamy; Frederic Bibeau; Michelle Nouaille; Virginie Loriot; Anne-Sophie Jarrousse; Franck Molina; Muriel Mathonnet; Denis Pezet; Marc Ychou
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

4.  Liquid Biopsy in Breast Cancer: Circulating Tumor Cells and Circulating Tumor DNA.

Authors:  Tae-Kyung Yoo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

Authors:  Bert Gold; Milena Cankovic; Larissa V Furtado; Frederick Meier; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2015-05       Impact factor: 5.568

6.  Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma.

Authors:  Kai Ding; Xiaoshuang Chen; Yihao Wang; Hui Liu; Wenjing Song; Lijuan Li; Guojin Wang; Jia Song; Zonghong Shao; Rong Fu
Journal:  Int J Clin Oncol       Date:  2017-02-16       Impact factor: 3.402

7.  Release of bulk cell free DNA during physical exercise occurs independent of extracellular vesicles.

Authors:  Susanne Helmig; Carsten Frühbeis; Eva-Maria Krämer-Albers; Perikles Simon; Suzan Tug
Journal:  Eur J Appl Physiol       Date:  2015-07-01       Impact factor: 3.078

8.  Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma.

Authors:  Kristina Warton; Nicole L Yuwono; Mark J Cowley; Mark J McCabe; Alwin So; Caroline E Ford
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

Review 9.  Characterizing the Cancer Genome in Blood.

Authors:  Sarah-Jane Dawson
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

Review 10.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

Authors:  Marius Ilie; Véronique Hofman; Elodie Long; Olivier Bordone; Eric Selva; Kevin Washetine; Charles Hugo Marquette; Paul Hofman
Journal:  Ann Transl Med       Date:  2014-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.